Growth Investments through M&A and Other Means
First written in FY2017-Q1. 10 of 17 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2027-H1.
53 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「Sales of other diagnostic reagents exceeded the previous year, as demand gradually recovered and Kainos Co. newly became a consolidated subsidiary.」
Kainos Co., which became a subsidiary in March 2026, contributed to diagnostic reagent sales following consolidation, with the company disclosing the post-acquisition business impact. - FY2026AdvancedAnnual report
「In March 2026, the company made Kainos Co., Ltd., a clinical testing reagent manufacturer, a subsidiary through a joint investment with Development Bank of Japan Inc.」
The company made Kainos Co., Ltd., a clinical testing reagent manufacturer, a subsidiary through a joint investment. It aims to generate synergies through complementary diagnostic reagents, overseas sales channels, and the integration of joint procurement and logistics. - 2026-05-22AdvancedGeneral Meeting of Shareholders
「臨床検査薬メーカーであるカイノス社を日本政策投資銀行との共同出資により子会社化し、海外展開も含めシナジーの最大化を図っていくことといたしました。」
成長投資について、カイノス社の子会社化による体外診断薬分野のアライアンス強化を具体化した。 - FY2025AdvancedAnnual report
「In fiscal 2024, the company invested in a startup developing wearable electronic stethoscopes and a startup holding technology for high-performance optical films, focusing not only on reforming existing businesses but also on developing new businesses.」
As growth investments, the company invested in fiscal 2024 in startups involved in wearable electronic stethoscopes and high-performance optical films. - FY2024-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 10 October 2023, the company decided to establish a joint venture with SCG Chemicals Public Company Limited, a wholly owned subsidiary of Siam Cement Public Company Limited, which is listed on the Stock Exchange of Thailand, to manufacture and sell acetylene black, and to construct an acetylene black production plant in Map Ta Phut, Rayong Province, Thailand. SCG Chemicals Public Company Limited is headquartered in Bangkok, Thailand, and its president and representative director is Tanawong Areeratchakul; it is referred to below as SCGC.」
The company decided to establish a joint venture with SCGC and construct an acetylene black production plant in Thailand. The investment will be US$400 million, annual production capacity will be 11,000 tonnes, and completion is scheduled for the first half of 2026, with operations scheduled to begin in the second half of the same year. - FY2023AdvancedAnnual report
「To this end, the company plans to invest a total of ¥360,000 million in strategic investments and ¥180,000 million in research and development over eight years, targeting operating profit of ¥100,000 million or more in 2030. In parallel, it will make environmental investments totaling ¥85,000 million over eight years to contribute to the planet and further enhance its social value,」
For Mission 2030, the company has specified an investment allocation of ¥360,000 million in strategic investments, ¥180,000 million in research and development, and ¥85,000 million in environmental investments for fiscal 2023 through fiscal 2030. - FY2023-Q3RaisedAnnual report
「Looking ahead to the next management plan for fiscal 2023 through fiscal 2030, the company will pursue a growth strategy through M&A, investments to expand production capacity, and the early creation of new businesses aimed at addressing social issues, with the goal of achieving sustainable corporate growth.」
The company has indicated a policy of pursuing M&A, production-capacity expansion and new-business creation as growth strategies under the next management plan for fiscal 2023 through fiscal 2030. The new plan also sets investment approvals of ¥540,000 million. - FY2023-Q2RestatedAnnual report
「Looking ahead to the next management plan for fiscal 2023 through fiscal 2030, the company will pursue a growth strategy through M&A, investments to expand production capacity, and the early creation of new businesses aimed at addressing social issues, with the goal of achieving sustainable corporate growth.」
The company has indicated a policy of continuing growth investments in M&A, investments to expand production capacity, and the creation of new businesses as initiatives under the next management plan for fiscal 2023 through fiscal 2030. - FY2021RaisedAnnual report
「Five-year plan: ¥200,000 million (strategic investments ¥75,000 million; ordinary investments ¥125,000 million) Five-year forecast: ¥210,000 million (strategic investments ¥85,000 million; ordinary investments ¥125,000 million)」
The company has revised its five-year investment forecast under Denka Value-Up to ¥210,000 million and strategic investments to ¥85,000 million, up from the initial plan of ¥200,000 million and ¥75,000 million, respectively. - FY2019AdvancedAnnual report
「Five-year total ¥200,000 million Of which: strategic investments ¥75,000 million (¥15,000 million per year) M&A and other initiatives ¥60,000 million Process reform ¥15,000 million」
For Denka Value-Up, the company has specified an allocation of ¥200,000 million over five years, comprising ¥75,000 million in strategic investments, ¥60,000 million in M&A and other initiatives, and ¥15,000 million for process reform. - FY2018-Q3RestatedAnnual report
「Fixed assets increased by ¥61,960 million from the end of the previous consolidated fiscal year to ¥292,238 million, mainly due to the increase in goodwill associated with making consolidated subsidiary Icon Genetics GmbH a wholly owned subsidiary.」
The company describes the increase in goodwill associated with making Icon Genetics GmbH a wholly owned subsidiary as a change in its financial position, but does not indicate a new acquisition milestone. - FY2018-Q2AdvancedAnnual report
「On 20 August 2015, the company acquired 51% of the shares in Icon Genetics GmbH held by Nomad Bioscience GmbH and made Icon Genetics GmbH a subsidiary. On 21 August 2017, it acquired the remaining 49% of the shares and completed the process of making Icon Genetics GmbH a wholly owned subsidiary.」
The company acquired the remaining 49% of Icon Genetics GmbH and completed the process of making it a wholly owned subsidiary. Growth investment in the healthcare field through M&A is making concrete progress. - FY2018-Q1RestatedAnnual report
「In 2014, in addition to formulating a shareholder return policy specifying the allocation to shareholders of earnings, the final outcome of the plan, the company clarified the sources of funds for strategic investments, including M&A, aimed at further growth.」
The company is reiterating its policy of clarifying sources of funds for strategic investments, including M&A, alongside shareholder returns. - FY2017AdvancedAnnual report
「In the infrastructure field, as part of efforts in the specialty admixture materials business in Southeast Asia, where economic growth has been significant, the company made a construction materials manufacturer in Indonesia a subsidiary, following its move into Malaysia.」
The company raised its investment ratio in PT ESTOP INDONESIA from 33% to 79% and made it a subsidiary. It is concretely executing growth investments through M&A and other initiatives. - FY2017-Q3RestatedAnnual report
「In 2014, in addition to formulating a shareholder return policy specifying the allocation to shareholders of earnings, the final outcome of the plan, the company clarified the sources of funds for strategic investments, including M&A, aimed at further growth.」
The company is reiterating its policy of clarifying sources of funds for strategic investments, including M&A, aimed at further growth. - FY2017-Q2AdvancedAnnual report
「Following the acquisition of shares in Icon Genetics GmbH during the second quarter of the fiscal year, the company has included it in the scope of consolidation. The increase in goodwill resulting from this event was ¥4,914 million for the cumulative second quarter of the fiscal year.」
The company acquired shares in Icon Genetics GmbH and included it in the scope of consolidation. The resulting increase in goodwill was ¥4,914 million. - FY2017-Q1First statedAnnual report
「In addition to formulating a shareholder return policy specifying the allocation to shareholders of earnings, the final outcome of the plan, we have clarified the sources of funds for strategic investments, including M&A, aimed at further growth.」
Alongside shareholder returns, the company has clarified sources of funds for strategic investments, including M&A, to support further growth.